Mara Goldstein
Stock Analyst at Mizuho
(2.68)
# 1,940
Out of 4,786 analysts
74
Total ratings
41.82%
Success rate
5.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $7 → $9 | $6.19 | +45.40% | 6 | Dec 19, 2024 | |
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $7.05 | +353.90% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $8.17 | +414.08% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $11.23 | +345.24% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $13.18 | +241.43% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $60.60 | +27.06% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.52 | +360.53% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $0.85 | +841.95% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.32 | +3,690.27% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $3.56 | +742.70% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.74 | +712.68% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $3.38 | +3.55% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.20 | +6,019.33% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $1.64 | +1,119.51% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $89.23 | +45.69% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $0.63 | +218.37% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.66 | +622.89% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.21 | +4,268.93% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $43.19 | -53.69% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $5.08 | +844.88% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.93 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $4.93 | +183.98% | 1 | Oct 12, 2017 |
Verastem
Dec 19, 2024
Maintains: Outperform
Price Target: $7 → $9
Current: $6.19
Upside: +45.40%
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $7.05
Upside: +353.90%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $8.17
Upside: +414.08%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $11.23
Upside: +345.24%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.18
Upside: +241.43%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $60.60
Upside: +27.06%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.52
Upside: +360.53%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $0.85
Upside: +841.95%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.32
Upside: +3,690.27%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $3.56
Upside: +742.70%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.74
Upside: +712.68%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $3.38
Upside: +3.55%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.20
Upside: +6,019.33%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.64
Upside: +1,119.51%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $89.23
Upside: +45.69%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $0.63
Upside: +218.37%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.66
Upside: +622.89%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.21
Upside: +4,268.93%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $43.19
Upside: -53.69%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $5.08
Upside: +844.88%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $19.93
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $4.93
Upside: +183.98%